Literature DB >> 10604958

Diphenyleneiodium chloride blocks inflammatory cytokine-induced up-regulation of group IIA phospholipase A(2) in rat mesangial cells.

G Dorsam1, M M Taher, K C Valerie, N B Kuemmerle, J C Chan, R C Franson.   

Abstract

Inflammatory cytokines, interleukin 1beta and tumor necrosis factor-alpha, potently stimulate rat mesangial cells to express and secrete group IIA phospholipase A(2) (PLA(2)). Cytokine-induced up-regulation of PLA(2) has been blocked by inhibitors (antioxidants) of the transcription factor, nuclear factor-kappaB (NF-kappaB), suggesting a role for NF-kappaB in the regulation of group IIA PLA(2) expression. Reactive oxygen species such as H(2)O(2), which are elevated in mesangial cells after cytokine activation, can mimic cytokine-induced NF-kappaB activation. However, the source of reactive oxygen species generation in mesangial cells, produced by cytokine stimulation, has yet to be clarified. Recently, tumor necrosis factor-alpha has been demonstrated to increase superoxide radical generation in mesangial cells. Therefore, we hypothesized that a selective NADPH oxidase inhibitor, diphenyleneiodium chloride (DPI), could block cytokine-induced group IIA PLA(2) up-regulation by attenuating NF-kappaB binding. To test this hypothesis, we isolated rat mesangial cells and characterized them by ultrastructural and immunochemical methods. This homogeneous mesangial cell population was responsive to cytokine as evidenced by an increase in steady-state levels of group IIA PLA(2) mRNA and extracellular enzymatic activity over time. DPI (0.02-20 microM), added 90 min before cytokine activation, inhibited both group IIA PLA(2) mRNA and enzymatic activity in a concentration-dependent manner. By electrophoretic mobility shift analysis, cytokine activation also increased specific NF-kappaB binding to one of two NF-kappaB consensus elements in the rat group IIA PLA(2) promoter and also was suppressed by DPI pretreatment. Antibodies to NF-kappaB p65 (Rel A) and p50 (but not normal rabbit IgG) supershifted this retardation signal and verified the type of NF-kappaB species as the classical p50/p65 heterodimer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604958

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

2.  Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors.

Authors:  Valérie Antonio; Arthur Brouillet; Brigitte Janvier; Claire Monne; Gilbert Bereziat; Marise Andreani; Michel Raymondjean
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

3.  Diphenyleneiodonium inhibits NF-kappaB activation and iNOS expression induced by IL-1beta: involvement of reactive oxygen species.

Authors:  A F Mendes; A P Carvalho; M M Caramona; M C Lopes
Journal:  Mediators Inflamm       Date:  2001-08       Impact factor: 4.711

Review 4.  Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review.

Authors:  Masoumeh Mohammadi
Journal:  Int J Prev Med       Date:  2019-05-17

Review 5.  Oxidative stress, prooxidants, and antioxidants: the interplay.

Authors:  Anu Rahal; Amit Kumar; Vivek Singh; Brijesh Yadav; Ruchi Tiwari; Sandip Chakraborty; Kuldeep Dhama
Journal:  Biomed Res Int       Date:  2014-01-23       Impact factor: 3.411

Review 6.  Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress?

Authors:  Speranza Rubattu; Silvia Mennuni; Marco Testa; Mara Mennuni; Giorgia Pierelli; Beniamino Pagliaro; Erica Gabriele; Roberta Coluccia; Camillo Autore; Massimo Volpe
Journal:  Int J Mol Sci       Date:  2013-11-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.